1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949

Awaiting development [GID-TA11465] Expected publication date: TBC

  • Project information
  • Project documents

NIHRIO BN: 34858-Isatuximab-Bortezomib-Lenalidomide-Dexamethasone-for-Multiple-Myeloma-V1.0-OCT2023-NON-CONF-.pdf (nihr.ac.uk)